Basel – CRISPR Therapeutics has signed an exclusive licence with the Massachusetts Institute of Technology, allowing the Basel-based biopharmaceutical company to use its family of Lipid Nanoparticle technologies in its development programmes.
The Lipid Nanoparticle (LNP) technologies were developed in the Massachusetts Institute of Technology (MIT) lab of Dr Daniel G. Anderson, who also happens to be on the advisory board of CRISPR Therapeutics. The licence allows the Basel-based biopharmaceutical company to use the LNP technologies in its therapeutic development programmes. MIT is receiving an upfront technology access fee, milestones and royalties on licensed products that reach the market, according to a statement.
CRISPR Therapeutics creates targeted gene-based medicines to treat serious diseases and it will use LNP technologies for its in vivo gene editing applications. According to Chad Cowan, head of research at CRISPR Therapeutics, the company’s platform has already demonstrated very potent gene disruption in murine liver, and the LPD technologies will be used to further research on liver indications. The researchers are working to evaluate a range of different LNP technologies, and the developments from Dr Anderson’s lab are performing well.
The Basel-based biopharmaceutical company develops transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing platform, which allows for precise, directed changes to DNA. The technology was developed by the French geneticist Emmanuelle Charpentier, who is also the company’s scientific founder. Her technology was named ‘Breakthrough of the Year’ in 2015 by the journal Science.